Diabetes Antibody Standardization Program: evaluation of assays for autoantibodies to glutamic acid decarboxylase and islet antigen-2.

Unit for Diabetes and Coeliac Disease, Institution of Clinical Sciences, Clinical Research Centre, University Hospital MAS, Malmö, Sweden.
Diabetologia (Impact Factor: 6.88). 05/2008; 51(5):846-52. DOI: 10.1007/s00125-008-0967-2
Source: PubMed

ABSTRACT Islet autoantibodies are important in diabetes classification and risk assessment, and as endpoints in observational studies. The Diabetes Autoantibody Standardization Program (DASP) aims to improve and standardise measurement of autoantibodies associated with type 1 diabetes. We report results for glutamic acid decarboxylase autoantibodies (GADA) and islet antigen-2 autoantibodies (IA-2A) from three DASP workshops (2002--2005).
Up to 60 laboratories in 18 countries participated in each workshop. Participants received coded serum aliquots from 50 patients with newly diagnosed type 1 diabetes (median age 18 years, range 9-35 years) and 100 blood donor controls. Results were analysed using receiver operator characteristic (ROC) curves with sensitivity adjusted to 95% specificity in workshop controls.
GADA assays performed well in all three workshops (median area under the ROC curve [AUC] 0.94; interquartile range 0.91-0.95) and performance was similar to DASP 2000. Performance of IA-2A assays improved over the workshop programme. Median AUC was 0.81 (interquartile range 0.79-0.83) in DASP 2002, 0.82 (interquartile range 0.78-0.84) in 2003, and 0.85 (interquartile range 0.82-0.87) in 2005 (p < 0.0001). Performance of GADA ELISA improved between 2002 and 2005, and, in DASP 2005, achieved higher median AUC and adjusted sensitivity than RIA. IA-2A ELISA improved and, in DASP 2005, achieved AUCs equivalent to in-house RIA. Assays using IA-2ic or full length IA-2 clones were more sensitive than those using IA-2bdc, with higher AUC (p = 0.004).
GADA and IA-2A assays perform well in discriminating health and disease. The workshop format highlights systematic differences related to assay method and allows full evaluation of novel methods. The programme of autoantibody workshops in type 1 diabetes provides a model for other autoimmune diseases.

1 Bookmark
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Type 1 diabetes (T1D) results from the destruction of pancreatic insulin-producing beta cells and is strongly associated with the presence of islet autoantibodies. Autoantibodies to tyrosine phosphatase-like protein IA-2 (IA-2As) are considered to be highly predictive markers of T1D. We developed a novel lateral flow immunoassay (LFIA) based on a bridging format for the rapid detection of IA-2As in human serum samples. In this assay, one site of the IA-2As is bound to HA-tagged-IA-2, which is subsequently captured on the anti-HA-Tag antibody-coated test line on the strip. The other site of the IA-2As is bound to biotinylated IA-2, allowing the complex to be visualized using colloidal gold nanoparticle-conjugated streptavidin. For this study, 35 serum samples from T1D patients and 44 control sera from non-diabetic individuals were analyzed with our novel assay and the results were correlated with two IA-2A ELISAs. Among the 35 serum samples from T1D patients, the IA-2A LFIA, the in-house IA-2A ELISA and the commercial IA-2A ELISA identified as positive 21, 29 and 30 IA-2A-positive sera, respectively. The major advantages of the IA-2A LFIA are its rapidity and simplicity.
    PLoS ONE 07/2014; 9(7):e103088. · 3.53 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Il diabete mellito di tipo 1 (DMT1) è una malattia autoimmune cronica causata dalla selettiva distruzione delle cellule beta pancreatiche che producono insulina da parte di un processo infiammatorio mediato da linfociti T autoreattivi. I linfociti B giocano un ruolo importante nel processo autoimmune come cellule presentanti l’antigene e come precursori delle plasmacellule che producono autoanticorpi anti-insula pancreatica. Gli autoanticorpi anti-insula, inizialmente identificati nel siero di pazienti con DMT1 utilizzando la tecnica dell’immunofluorescenza indiretta su sezioni criostatiche di pancreas umano, sono diretti contro vari autoantigeni, fra cui i più importanti sono la decarbossilasi dell’acido glutammico (GAD65), la proteina tirosin-fosfatasi IA-2, l’insulina e il trasportatore dello zinco ZnT8. Questi autoanticorpi, che accompagnano il processo autoimmune e l’infiammazione intra-insulare pancreatica nota come insulite, non sono patogenetici, ma sono fondamentali marcatori del processo autoimmune utili a fini clinici. Quando dimostrabili nel siero di pazienti con malattia diabetica permettono di discriminare le forme autoimmuni dalle forme non autoimmuni della malattia. Così, in modo particolare, il diabete autoimmune latente dell’adulto (LADA) è identificato proprio dalla presenza di anticorpi anti-GAD65 (GADA) in soggetti non insulino-dipendenti che però presentano un alto rischio di sviluppare insulino-dipendenza entro pochi anni dalla diagnosi. Inoltre, la presenza in circolo di autoanticorpi anti-insula pancreatica permette di stimare il rischio futuro di sviluppo di DMT1 in soggetti normoglicemici. Summary Type 1 diabetes mellitus (T1DM) is a chronic autoimmune disease caused by the selective destruction of insulin-secreting pancreatic beta cells by a T-cell mediated inflammatory process. B-lymphocytes play a critical role as antigen-presenting cells and as precursors of plasma cells that produce islet autoantibodies. Islet autoantibodies originally identified in sera from patients with T1DM by the indirect immunofluorescence technique on criostatic sections of human pancreas are directed against several autoantigens, such as insulin, glutamic acid decarboxylase (GAD65), protein-tyrosin phosphatase IA-2 and zinc transporter T8 (ZnT8). These autoantibodies are not pathogenic, but they are useful clinical markers of the ongoing autoimmune process. When present in the serum of patients with diabetes mellitus they enable the discrimination between autoimmune and non autoimmune forms. More specifically, latent autoimmune diabetes in adults (LADA) is identified by the presence of GAD65 autoantibodies (GADA) in subjects with non-insulin-dependent diabetes, but with an increased risk for the future development of insulin-dependency. Furthermore, the presence of circulating islet autoantibodies enables the estimate of the risk for the future development of T1DM in normoglycemic individuals.
    Rivista Italiana della Medicina di Laboratorio 12/2013; 9(4):209-217.
  • [Show abstract] [Hide abstract]
    ABSTRACT: S3-Leitlinie der Deutschen Diabetes-Gesellschaft (DDG). [S3-Guideline of the German Diabetes Association (DDG)]
    Diabetologie und Stoffwechsel 08/2011; 8(Suppl.2):S.133-S.143. · 0.43 Impact Factor


Available from